CLINICAL_TRIALS
trial_result
· 2021-06-30
Clinical Trial Update: A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus [Phase 2]
Summary
A Phase 2 efficacy and safety study of Dapirolizumab Pegol (DZP) in systemic lupus erythematosus has completed with results posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: UCB Biopharma S.P.R.L. | Conditions: Systemic Lupus Erythematosus (SLE) | Phase 2 | Status: COMPLETED | Results posted: 2021-06-30